Isoflurane promotes proliferation and invasion of cervical carcinoma cells via downregulation of miR-375 expression

Objective: Isoflurane is a widely used volatile anesthetic. The aim of the current study was to evaluate effects of isoflurane on the behavior of human cervical cancer (CC) cells and the molecular mechanisms related with this activity. Materials and Methods: The effects of isoflurane on CC cell proliferation, apoptosis, and invasion were detected by CCK-8 assay, flow cytometry, and matrigel invasion assay. Real-time PCR was used to assess miR-375 expression. MiR-375 mimics were transfected into CC cells to upregulate miR-375 levels. Results: Isoflurane significantly promoted CC cell proliferation and invasion, and suppressed cell apoptosis. Isoflurane also efficiently decreased miR-375 expression. Moreover, transfection of miR-375 mimics reversed the effects of isoflurane on the biological behavior of CC cells. Conclusions: The present data indicates that isoflurane could promote CC cell viability and invasion and inhibit cell apoptosis through the downregulation of miR-375.

Isoflurane; Cervical cancer; miR-375; Proliferation; Invasion.

[1] Arbyn M., Castellsague X., de Sanjose S., Bruni L., Saraiya M., Bray F., et al.: “Worldwide burden of cervical cancer in 2008”. Ann. Oncol., 2011, 22, 2675.

[2] Bartel D. P.: “MicroRNAs: genomics, biogenesis, mechanism, and function”. Cell, 2004, 116, 281.

[3] Wang S., Wu W.; Claret F.X.: “Mutual regulation of microRNAs and DNA methylation in human cancers”. Epigenetics, 2017, 12, 187.

[4] Cheung T.H., Man K.N., Yu M.Y., Yim S.F., Siu N.S., Lo K.W., et al.: “Dysregulated microRNAs in the pathogenesis and progression of cervical neoplasm”. Cell Cycle, 2012, 11, 2876.

[5] Wang B., Lv K., Chen W., Zhao J., Luo J., Wu J., et al.: “miR-375 and miR-205 Regulate the Invasion and Migration of Laryngeal Squamous Cell Carcinoma Synergistically via AKT-Mediated EMT”. Biomed. Res. Int., 2016, 2016, 9652789.

[6] Wang X.Z., Hang Y. K., Liu J.B., Hou Y.Q., Wang N., Wang M.J.: “Over-expression of microRNA-375 inhibits papillary thyroid carcinoma cell proliferation and induces cell apoptosis by targeting ERBB2”. J. Pharmacol. Sci., 2016, 130, 78.

[7] Yi J., Jin L., Chen J., Feng B., He Z., Chen L., et al.: “MiR-375 suppresses invasion and metastasis by direct targeting of SHOX2 in esophageal squamous cell carcinoma”. Acta Biochim. Biophys. Sin. (Shanghai), 2017, 49, 159.

[8] Yu H., Jiang L., Sun C., Li Guo L., Lin M., Huang J., et al.: “Decreased circulating miR-375: a potential biomarker for patients with non-small-cell lung cancer”. Gene, 2014, 534, 60.

[9] Lian S., Park J.S., Xia Y., Nguyen T.T., Joo Y.E., Kim K.K., et al.: “MicroRNA-375 Functions as a Tumor-Suppressor Gene in Gastric Cancer by Targeting Recepteur d’Origine Nantais”. Int. J. Mol. Sci., 2016, 17, pii: E1633.

[10] Zhou N., Wu J., Wang X., Sun Z., Han Q., Zhao L.: “Low-level expression of microRNA-375 predicts poor prognosis in hepatocellular carcinoma”. Tumour Biol., 2016, 37, 2145.

[11] Cui F., Wang S., Lao I., Zhou C., Kong H., Bayaxi N., et al.: “miR375 inhibits the invasion and metastasis of colorectal cancer via targeting SP1 and regulating EMT-associated genes”. Oncol. Rep., 2016, 36, 487.

[12] Yonemori K., Seki N., Kurahara H., Osako Y., Idichi T., Arai T., et al.: “ZFP36L2 promotes cancer cell aggressiveness and is regulated by antitumor microRNA-375 in pancreatic ductal adenocarcinoma”. Cancer Sci., 2017, 108, 124.

[13] Wang F., Li Y., Zhou J., Xu J., Peng C., Ye F., et al.: “miR-375 is down-regulated in squamous cervical cancer and inhibits cell migration and invasion via targeting transcription factor SP1”. Am. J. Pathol., 2011, 179, 2580.

[14] Yu X., Zhao W., Yang X., Wang Z., Hao M.: “miR-375 Affects the Proliferation, Invasion, and Apoptosis of HPV16-Positive Human Cervical Cancer Cells by Targeting IGF-1R”. Int. J. Gynecol. Cancer, 2016, 26, 851.

[15] Song L., Liu S., Zeng S., Zhang L., Li X.: “miR-375 Modulates Radiosensitivity of HR-HPV-Positive Cervical Cancer Cells by Targeting UBE3A through the p53 Pathway”. Med. Sci. Monit., 2015, 21, 2210.

[16] Vahabi S.; Eatemadi A.: “Effects of anesthetic and analgesic techniques on cancer metastasis”. Biomed Pharmacother., 2017, 87, 1.

[17] Kim R.: “Anesthetic technique and cancer recurrence in oncologic surgery: unraveling the puzzle”. Cancer Metastasis Rev., 2017, 36, 159.

[18] Zhang W., Shao X.: “Isoflurane Promotes Non-Small Cell Lung Cancer Malignancy by Activating the Akt-Mammalian Target of Rapamycin (mTOR) Signaling Pathway”. Med. Sci. Monit., 2016, 22, 4644.

[19] Huang H., Benzonana L.L., Zhao H., Watts H.R., Perry N.J., Bevan C., et al.: “Prostate cancer cell malignancy via modulation of HIF1alpha pathway with isoflurane and propofol alone and in combination”. Br. J. Cancer, 2014, 111, 1338.

[20] Luo X., Zhao H., Hennah L., Ning J., Liu J., Tu H., et al.: “Impact of isoflurane on malignant capability of ovarian cancer in vitro”. Br J Anaesth, 2015, 114, 831.

[21] Benzonana L.L., Perry N.J., Watts H.R., Yang B., Perry I.A., Coombes C., et al.: “Isoflurane, a commonly used volatile anesthetic, enhances renal cancer growth and malignant potential via the hypoxia-inducible factor cellular signaling pathway in vitro”. Anesthesiology, 2013, 119, 593.

[22] Duff S., Connolly C., Buggy D. J.: “Adrenergic, Inflammatory, and Immune Function in the Setting of Oncological Surgery: Their Effects on Cancer Progression and the Role of the Anesthetic Technique in their Modulation”. Int. Anesthesiol. Clin., 2016, 54, 48.

[23] Xuan W., Zhao H., Hankin J., Chen L., Yao S., Ma D.: “Local anesthetic bupivacaine induced ovarian and prostate cancer apoptotic cell death and underlying mechanisms in vitro”. Sci. Rep., 2016, 6, 26277.

[24] Yang N., Liang Y., Yang P., Yang T., Jiang L.: “Propofol inhibits lung cancer cell viability and induces cell apoptosis by upregulating microRNA-486 expression”. Braz J Med Biol Res, 2017, 50, e5794.

[25] Banno K., Iida M., Yanokura M., Kisu I., Iwata T., Tominaga E., et al.: “MicroRNA in cervical cancer: OncomiRs and tumor suppressor miRs in diagnosis and treatment”. ScientificWorldJournal, 2014, 2014, 178075.

[26] Li J., Liu Q., Clark L. H., Qiu H., Bae-Jump V.L., Zhou C.: “Deregulated miRNAs in human cervical cancer: functional importance and potential clinical use”. Future Oncol., 2017, 13, 743.

[27] Jimenez-Wences H., Martinez-Carrillo D.N., Peralta-Zaragoza O., Campos-Viguri G.E., Hernandez-Sotelo D., Jimenez-Lopez M.A., et al.: “Methylation and expression of miRNAs in precancerous lesions and cervical cancer with HPV16 infection”. Oncol. Rep., 2016, 35, 2297.

[28] Tatekawa S., Chinen Y., Ri M., Narita T., Shimura Y., MatsumuraKimoto Y., et al.: “Epigenetic repression of miR-375 is the dominant mechanism for constitutive activation of the PDPK1/RPS6KA3 signalling axis in multiple myeloma”. Br. J. Haematol., 2017, 178, 534.

[29] Garikipati V. N., Verma S.K., Jolardarashi D., Cheng Z., Ibetti J., Cimini M., et al.: “Therapeutic inhibition of miR-375 attenuates postmyocardial infarction inflammatory response and left ventricular dysfunction via PDK-1-AKT signalling axis”. Cardiovasc. Res., 2017, 113, 938.

[30] Yin L.H., Zheng X.Q., Li H.Y., Bi L.X., Shi Y.F., Ye A.F., et al.: “Epigenetic deregulated miR-375 contributes to the constitutive activation of JAK2/STAT signaling in myeloproliferative neoplasm”. Leuk. Res., 2015, 39, 471.

[31] Wei R., Yang Q., Han B., Li Y., Yao K., Yang X., et al.: “microRNA375 inhibits colorectal cancer cells proliferation by downregulating JAK2/STAT3 and MAP3K8/ERK signaling pathways”. Oncotarget, 2017, 8, 16633.

[32] Abraham K.J., Zhang X., Vidal R., Pare G.C., Feilotter H.E., Tron V. A.: “Roles for miR-375 in Neuroendocrine Differentiation and Tumor Suppression via Notch Pathway Suppression in Merkel Cell Carcinoma”. Am. J. Pathol., 2016, 186, 1025.